U.S. IPO Weekly Recap: Oncology Biotech Aprea Therapeutics Finishes On Top In 4-IPO Week [Seeking Alpha]
Aprea Therapeutics, Inc. (APRE)
Company Research
Source: Seeking Alpha
U.S. IPO Weekly Recap: Oncology Biotech Aprea Therapeutics Finishes On Top In 4-IPO Week Summary Six companies were scheduled to price this past week, but only four entered the public market. The top performer this week was Phase 3 oncology biotech Aprea Therapeutics which priced an $85 million upsized IPO at the midpoint. AstraZeneca's spin-off Viela Bio priced its IPO at the low end, raising $150 million at a $986 million valuation. Even biotechs aren't immune to the newly-challenging IPO market. Six companies were scheduled to price this past week, but only four entered the public market; one biotech postponed while another - the largest - withdrew its IPO plans. All four priced at or below the midpoint. There was also a spike in initial filings, with eight companies and one SPAC entering the IPO pipeline. APRE AstraZeneca's (NYSE: AZN VIE Two companies broke issue on their first day of trading. Degenerative disease biotech Frequency Therapeutics FREQ MetroCity Bankshares MCBS Of
Show less
Read more
Impact Snapshot
Event Time:
APRE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
APRE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
APRE alerts
High impacting Aprea Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
APRE
News
- Aprea Therapeutics, Inc. (NASDAQ: APRE) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.MarketBeat
- Here's Why Aprea Therapeutics (APRE) Could be Great Choice for a Bottom Fisher [Yahoo! Finance]Yahoo! Finance
- Aprea Therapeutics Third Quarter 2024 Earnings: Beats Expectations [Yahoo! Finance]Yahoo! Finance
- Aprea Therapeutics, Inc. (APRE) Reports Q3 Loss, Lags Revenue Estimates [Yahoo! Finance]Yahoo! Finance
- Aprea Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business UpdateGlobeNewswire
APRE
Sec Filings
- 11/14/24 - Form SCHEDULE
- 11/8/24 - Form 8-K
- 11/8/24 - Form 424B5
- APRE's page on the SEC website